There are now 7 funds that have either taken a new position or added to their position since July 1. There are six funds from the original deal and the 7th is Sabby Mgt who filed yesterday...
Tengion Announces Transactions Totaling $33.6 Million to Advance its Organ Regeneration Platform™
WINSTON-SALEM, N.C., July 1, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the closing of transactions totaling $33.6 million to fund its two lead clinical programs, the Neo-Kidney Augment™ and the Neo-Urinary Conduit™.
As part of the $33.6 million in transactions, Tengion announced a strategic investment from Celgene Corporation in the form of a $15 million payment in cash, in return for which Celgene was granted a right of first negotiation on Tengion's Neo-Kidney Augment program. Celgene also entered into a collaboration and obtained an exclusive option to acquire assets, including the rights to utilize the Company's technology, related to the development of a neo-esophageal implant. Celgene has also received warrants to purchase shares of Tengion's common stock. Celgene invested $5 million in the Company's October 2012 financing.
Tengion also announced the closing of an $18.6 million financing in which the Company issued Senior Secured Convertible Notes (the "Notes"). Investors in the Notes included both existing investors RA Capital Management LLC, Deerfield Management Company, LP, Bay City Capital, and HealthCap, in addition to new investors that included Perceptive Life Sciences and QVT Financial LP.
Market Data 
Markets 
AI
